Ceftazidime-avibactam: new rules for the game against multidrug-resistant gram-negative bacteria

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):24-34

Type
Journal article

Abstract

The rapid spread of multidrug-resistant Gram-negative bacteria in hospital settings all over the world makes a demand for the new options to overcome antimicrobial resistance. Ceftazidime-avibactam is the first approved antibiotic that contains a new beta-lactamase inhibitor with unique properties. This review provides insight into the spectrum of activity, pharmacological characteristics, data on efficacy and safety of ceftazidime-avibactam obtained from the clinical trials and real clinical practice, as well as prospects for further studies and clinical application of this new antimicrobial agent.

Views
0 Abstract
0 PDF
0 BibTeX
Shared
0
0
0
0
0
0